EC Number   |
Activating Compound |
Reference |
|---|
   2.7.3.2 | aripiprazole |
activation of enzyme in striatum and cerebral cortex after chronic administration at 10 or 20 mg/kg. No effect on enzyme in hippocampus, cerebellum and prefrontal cortex |
671679 |
| 2.7.3.2 | trans-[RuCl2(3,4-pyridinedicarboxylic acid)4] |
administration at 180.7 micromol/kg, increase of creatine kinase activity in hippocampus, striatum, cerebral cortex and heart, but not in skeletal muscle. No effect on enzyme in vitro |
675240 |
| 2.7.3.2 | trans-[RuCl2(3,5-pyridinedicarboxylic acid)4] |
administration at 180.7 micromol/kg, increase of creatine kinase activity in hippocampus, striatum, cerebral cortex and heart, but not in skeletal muscle. No effect on enzyme in vitro |
675240 |
| 2.7.3.2 | 20(S)-protopanaxadiol |
best activator |
760706 |
| 2.7.3.2 | 20(S)-protopanaxadiol |
best activator of isoform CK-MM, 54.3% increase of activity at 0.04 mM |
760706 |
| 2.7.3.2 | more |
increase of enzymatic activity post-exercise |
697687 |
| 2.7.3.2 | NADH |
lowers Km for phosphocreatine 3fold |
642417 |
| 2.7.3.2 | more |
not influenced by panaxatriol, ocotillol, ginsenoside Rg1, and ginsenoside Rd |
760706 |
| 2.7.3.2 | more |
panaxatriol, ocotillol, ginsenoside Rg1, and ginsenoside Rd have no significant influence on the enzyme activity |
760706 |
| 2.7.3.2 | 20(R)-protopanaxadiol |
significantly increases the enzyme activity |
760706 |
